alkaline phosphatase Inhibitors
2 drugsAbout alkaline phosphatase
Alkaline phosphatase (ALP) is an enzyme that catalyzes the hydrolysis of phosphate monoesters, playing a crucial role in various biological processes throughout the body.
While ALP's involvement in fundamental physiological functions makes it a potential therapeutic target, there is currently no genetic evidence directly linking it to specific diseases.
Two FDA-approved small molecule drugs, MULTRYS and TRALEMENT, target alkaline phosphatase, both approved in 2020 by AM REGENT for therapeutic areas outside major indications.
Top alkaline phosphatase Drugs
AM REGENT is the only company with approved drugs targeting alkaline phosphatase.
The lack of competition suggests a high barrier to entry or limited market interest.
alkaline phosphatase Drug Modality Landscape
Modalities
Routes of Administration
alkaline phosphatase is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or biologics could provide a competitive advantage.
alkaline phosphatase Clinical Trials 32 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alkaline phosphatase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 10 | 8 | 0 | 2 | 100% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alkaline phosphatase Drug Approval Timeline (2020 - 2020)
The first and most recent drugs were approved in 2020, indicating a recent entry into the market.
The recent approvals suggest a potential for growth, but also a risk of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 27 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alkaline phosphatase. A trial counts if an approved drug acting on alkaline phosphatase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.